Skip to main content
. 2017 Nov 13;7:15428. doi: 10.1038/s41598-017-15832-5

Figure 2.

Figure 2

5-HT, 5-Htr1a specific agonist and 5-Htr1b specific agonist down-regulates AR expression in rat ventral prostate. (a) Western blot analysis of AR expression in prostate explants treated with increasing doses of 5-HT, specific 5-Htr1a agonist, 8-OH-DPAT, and specific 5-Htr1b agonist, anpirtoline. (b) Quantification of AR protein in VPs treated with different concentrations of 5-HT in medium conditions without or with testosterone supplementation, n ≥ 3 (each sample contained a pool of 4 VPs). (c) Quantification of AR protein in VPs treated with different concentrations of 8-OH-DPAT in medium conditions without or with testosterone supplementation, n ≥ 3 (each sample contained a pool of 4 VPs). (d) Quantification of AR protein in VPs treated with different concentrations of Anpirtoline in medium conditions without or with testosterone supplementation, n ≥ 3 (each sample contained a pool of 4 VPs). Error bars indicate s.e.m. n.s. non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; two-way ANOVA and Bonferroni post hoc test. VPs, ventral prostate explants; AR, androgen receptor; AU, arbitrary units; 5-HT, serotonin.